Abstract: The present invention relates to a novel class of seeded nanoparticles and uses thereof.

Abstract: Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.

Abstract: The invention provides a process for the preparation of bismuth oxyhalide, comprising a precipitation of bismuth oxyhalide in an acidic aqueous medium in the presence of a reducing agent. Also provided are bismuth oxyhalide compounds doped with elemental bismuth Bi(0). The use of Bi(0) doped bismuth oxyhalide as photocatalysts in water purification is also described.

Abstract: Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, one or more metabolic syndrome conditions or complications and/or cancer comprising administering an effective amount of ostreolysin, its functionally related variant, or an extract or mushroom extract comprising the same to subjects in need thereof.

Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.

Abstract: Provided is a novel class of solid water-dispersible powders, including a plurality of water-insoluble photoinitiators in nanoparticle forms for use in water-based ink formulations.

Abstract: The invention disclosed herein generally provides implantable medical devices and implants that may be removed on-demand from a subject's body at any time after their implanting in the body, without necessitating invasive procedures.

Abstract: Systems and method for classifying EEG signals of a human subject generated responsive to a series of images containing target images and non-target images. The EEG signals are in a spatio-temporal representation. The time points are classified independently, using a linear discriminant classifier, to compute spatio-temporal discriminating weights that are used to amplify the spatio-temporal representation, to create a spatially-weighted representation. Principal Component Analysis is used on a temporal domain for dimensionality reduction, separately for each spatial channel of the signals, to create a projection, which is applied to the spatially-weighted representation onto a first plurality of principal components, to create a temporally approximated spatially weighted representation.

Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.

Abstract: An air treatment unit may include an air inlet to receive a flow of input air for treatment and a reaction reservoir configured to hold an aqueous air treatment solution. The air treatment unit may also include an air dispersing element flow connected with the air inlet, wherein the air dispersing element is configured to convert at least a portion of the flow of input air into a plurality of microbubbles for introduction into the aqueous air treatment solution, such that an amount of one or more target gas species contained within the plurality of microbubbles is reduced through reaction with the aqueous air treatment solution. The unit may include an air outlet configured to output treated air from the reaction reservoir.

Abstract: The present invention provides an optically active structure and the use thereof in a backlight unit. The optically active structure comprises a plurality of optically active particles configured to emit light of one or more predetermined wavelength range in response to pumping energy, and a plurality of light scattering elements. The plurality of light scattering elements comprises optically transparent void regions, such as void regions surrounding filler particles.

Abstract: Provided is a unique class of foam materials characterized by regions of material unidirectionality. The foam materials are configured for a great variety of end-use applications as core materials or as materials in construction of multilayered structures. The novel and ingenious process for making the composite materials of the invention, permits modifying the foam materials to suite any specific end use.

Abstract: A method of determining the methylation status of at least one methylation site of a double-stranded DNA molecule is disclosed. The method comprises analyzing the methylation status of both the forward strand and the reverse strand of the DNA molecule.

Abstract: Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.

Abstract: Provided herein are pre-lyophilized compositions containing a nucleic acid, a cationic polymer, and a carbohydrate. Also provided are lyophilized compositions of matter and reconstituted compositions as well as methods of making using the same for treating tumors in patients.

Abstract: Provided are methods, compositions and kits employing cellulose nanocrystals for hair-straightening treatment. Also provided are methods, compositions and kits employing a resilin, for hair-straightening treatment and/or for maintenance of straightened hair following a hair-straightening treatment.

Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.

Abstract: The invention provides a process for the production of hydrogen, comprising catalytically decomposing a concentrated aqueous solution of potassium formate in a reaction vessel to form bicarbonate slurry and hydrogen, discharging the hydrogen from said reaction vessel, and treating a mixture comprising the bicarbonate slurry and the catalyst with an oxidizer, thereby regenerating the catalyst. Pd/C catalysts useful in the process are also described.

Abstract: The present invention is directed to a fatty acid amide of an amino acid, including a stereoisomer and a salt thereof for use in the treatment of a patient suffering from any type of addiction disorder, substance abuse disorder, including any condition and symptom associated therewith and including withdrawal syndrome and relapse addiction during and after a rehabilitation treatment of said patient.

Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.